Zaltenibart

N/A

Report date: 2025/04/28 16:53:52

Base Information

Drug NameZaltenibart
Drug Alias NameOMS-906
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionMannose-binding lectin associated serine protease-3 inhibitors
TargetsMannose-binding lectin associated serine protease-3
Therapy Area/IndicationsC3 glomerulopathyHemoglobinuria, ParoxysmalGlomerulonephritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUkrainePolandNew Zealand +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of LeicesterMedical Research CouncilHelion Biotech APS
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk A/SOmeros Corp
Inactive CompaniesN/A
Active IndicationsC3 glomerulopathyHemoglobinuria, ParoxysmalGlomerulonephritis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A